NASDAQ:BGNE - Beigene Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$133.85 +2.43 (+1.85 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$133.85
Today's Range$129.23 - $134.87
52-Week Range$92.04 - $220.10
Volume437,945 shs
Average Volume733,893 shs
Market Capitalization$7.81 billion
P/E Ratio-60.02
Dividend YieldN/A
Beta1.81
BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has strategic collaborations with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 inhibitor, BGB-A317; Merck KGaA to research and develop on BGB-290 and BGB-283; and MEI Pharma, Inc. to evaluate the safety and efficacy of ME-401, an investigational PI3K delta inhibitor in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BGNE
Previous Symbol
CUSIPN/A
Phone34-59-494-12

Debt

Debt-to-Equity Ratio0.09
Current Ratio11.57
Quick Ratio11.47

Price-To-Earnings

Trailing P/E Ratio-60.02
Forward P/E Ratio-13.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$238.39 million
Price / Sales33.36
Cash FlowN/A
Price / Cash FlowN/A
Book Value$15.02 per share
Price / Book8.91

Profitability

EPS (Most Recent Fiscal Year)($2.23)
Net Income$-93,100,000.00
Net Margins-320.08%
Return on Equity-38.44%
Return on Assets-29.62%

Miscellaneous

Employees900
Outstanding Shares59,410,000
Market Cap$7.81 billion
OptionableOptionable

Beigene (NASDAQ:BGNE) Frequently Asked Questions

What is Beigene's stock symbol?

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

How were Beigene's earnings last quarter?

Beigene Ltd (NASDAQ:BGNE) released its quarterly earnings results on Wednesday, November, 7th. The company reported ($2.53) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($2.97) by $0.44. The firm earned $54.20 million during the quarter, compared to analyst estimates of $47.06 million. Beigene had a negative return on equity of 38.44% and a negative net margin of 320.08%. The business's revenue for the quarter was down 75.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.54 EPS. View Beigene's Earnings History.

When is Beigene's next earnings date?

Beigene is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Beigene.

What price target have analysts set for BGNE?

11 brokerages have issued twelve-month price objectives for Beigene's stock. Their forecasts range from $138.00 to $215.00. On average, they anticipate Beigene's stock price to reach $178.7188 in the next twelve months. This suggests a possible upside of 33.5% from the stock's current price. View Analyst Price Targets for Beigene.

What is the consensus analysts' recommendation for Beigene?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beigene.

What are Wall Street analysts saying about Beigene stock?

Here are some recent quotes from research analysts about Beigene stock:
  • 1. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (11/8/2018)
  • 2. Maxim Group analysts commented, "BeiGene presented preliminary data from its ongoing P1/2 study of anti- PD1 tislelizumab in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)." (9/20/2018)

Has Beigene been receiving favorable news coverage?

News coverage about BGNE stock has trended somewhat positive on Saturday, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Beigene earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term.

Who are some of Beigene's key competitors?

Who are Beigene's key executives?

Beigene's management team includes the folowing people:
  • Mr. John V. Oyler, Co-Founder, CEO & Chairman (Age 50)
  • Dr. Heng Liang, CFO & Chief Strategy Officer (Age 55)
  • Dr. Amy C. Peterson, Chief Medical Officer of Immuno-Oncology (Age 51)
  • Dr. Jane E. Huang, Chief Medical Officer - Hematology (Age 45)
  • Dr. Xiaobin Wu, Pres & Gen. Mang. of China

When did Beigene IPO?

(BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Who are Beigene's major shareholders?

Beigene's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (10.17%), Hsbc Holdings PLC (4.89%), Capital Research Global Investors (3.40%), Canada Pension Plan Investment Board (2.08%), Vanguard Group Inc. (1.79%) and Vanguard Group Inc (1.79%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler and Xiaodong Wang. View Institutional Ownership Trends for Beigene.

Which major investors are selling Beigene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Artal Group S.A., Renaissance Technologies LLC, Credit Suisse AG, Barings LLC, Deutsche Bank AG, The Manufacturers Life Insurance Company and Folger Hill Asset Management LP. Company insiders that have sold Beigene company stock in the last year include Amy C Peterson, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler and Xiaodong Wang. View Insider Buying and Selling for Beigene.

Which major investors are buying Beigene stock?

BGNE stock was bought by a variety of institutional investors in the last quarter, including Hsbc Holdings PLC, Capital Research Global Investors, Pictet Asset Management Ltd., Canada Pension Plan Investment Board, Macquarie Group Ltd., Vanguard Group Inc, Vanguard Group Inc. and FMR LLC. View Insider Buying and Selling for Beigene.

How do I buy shares of Beigene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Beigene's stock price today?

One share of BGNE stock can currently be purchased for approximately $133.85.

How big of a company is Beigene?

Beigene has a market capitalization of $7.81 billion and generates $238.39 million in revenue each year. The company earns $-93,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Beigene employs 900 workers across the globe.

What is Beigene's official website?

The official website for Beigene is http://www.beigene.com.

How can I contact Beigene?

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 34-59-494-12 or via email at [email protected]


MarketBeat Community Rating for Beigene (NASDAQ BGNE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  332 (Vote Outperform)
Underperform Votes:  269 (Vote Underperform)
Total Votes:  601
MarketBeat's community ratings are surveys of what our community members think about Beigene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel